- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05294055
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
December 1, 2022 updated by: Qiu Lugui
A Prospective and Multicenter Clinical Study of Mecapegfilgrastim in Combination With Chemotherapy for Autologous Peripheral Blood Stem Cell Mobilization in Patients With Multiple Myeloma or Lymphoma
This is a multicenter prospective study to evaluate the efficacy and safety of chemotherapy combined with a single dose of subcutaneous(SC) injection mecapegfilgrastim on day 2 or day 5 after chemotherapy for autologous peripheral blood stem cell (PBSC) mobilization in patients with multiple myeloma or lymphoma.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Subjects eligible for autologous stem-cell transplantation are randomized to receive a single dose of 12mg mecapegfilgrastim SC on day 2 or day 5 after chemotherapy for PBSC mobilization.
According to the protocol, high-dose cyclophosphamide (50mg/kg or 2g/m2, for 2 days) is given to patients with MM, and high-dose etoposide (1.5-1.8g/m2,
single dose ) is administered to patients with lymphoma.
Apheresis is performed according to the standard institutional regulations.
The primary point is to evaluate the percentage of successful mobilization, defined as the cumulative collection of ≥2×10^6/kg CD34+ cells in three or fewer apheresis.
Study Type
Interventional
Enrollment (Anticipated)
120
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Anhui
-
Hefei, Anhui, China
- Not yet recruiting
- Anhui Provincial Hospital
-
-
Beijing
-
Beijing, Beijing, China
- Not yet recruiting
- Peking University Third Hospital
-
-
Henan
-
Zhengzhou, Henan, China
- Not yet recruiting
- Henan Cancer Hospital
-
-
Shandong
-
Jinan, Shandong, China
- Not yet recruiting
- Shandong Cancer Hospital
-
Contact:
- Zengjun Li
-
-
Tianjin
-
Tianjin, Tianjin, China, 300020
- Recruiting
- Institute of Hematology & Blood Diseases Hospital
-
Tianjin, Tianjin, China
- Not yet recruiting
- Tianjin Medical University General Hospital
-
Tianjin, Tianjin, China
- Recruiting
- Tianjin Medical University Cancer Institute & Hospital
-
Contact:
- Yafei Wang
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Lymphoma patients with ≤2 lines of prior therapy, patients with multiple myeloma with one line of therapy;
- Patients who had achieved at least partial response (PR);
- Patients who were eligible for autologous peripheral blood stem cell transplantation
- Age≥18 and≤65 years;
- Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Patients who have an estimated life expectancy of more than three months
- Fertile patients must be willing to use reliable contraception during the clinical study period and for 90 days after the last dose and have a negative serological pregnancy test within 72 hours prior to the first dose.
- Patients must be able and willing to give written informed consent prior to any study-related procedures
Exclusion Criteria:
- Patients who had previously attempted hematopoietic stem cell mobilization;
- Patients who had undergone previous bone marrow transplantation;
- Lymphoma patients with bone marrow involvement or patients with MM who had >10% bone marrow involvement at screening ;
- Patients with angina pectoris, myocardial infarction, coronary stent implantation, uncontrolled arrhythmias (atrial tachycardia, atrial fibrillation, persistent ventricular arrhythmias, etc.), cardiac insufficiency, Q-Tc interval >500ms, left ventricular ejection fraction (EF)<60%, or other heart diseases that the investigator considers unsuitable for hematopoietic stem cell mobilization or hematopoietic stem cell transplantation;
- Patients with uncontrolled pulmonary infection;
Patients who had any of the following laboratory indicators:
- White blood cell count(WBC)<2.5×109/L;
- Absolute neutrophil count(ANC)<1.5×109/L;
- Platelets count(PLT)<80×109/L;
- Creatinine > 2.0 X ULN of the reference range or creatinine clearance ≤60ml/min
- AST/ALT/Total bilirubin > 2.5 X ULN;
Patients who have received any of the following treatments:
- Patients who had been treated with more than 4 cycles of lenalidomide or received lenalidomide within 4 weeks prior to hematopoietic stem cell mobilization chemotherapy.
- Patients who previously been treated with fludarabine or melphalan;
- Patients who plan to receive radiation within 30 days after transplantation
- Patients who had received radiation therapy in the pelvis
- Patients allergic to Mecapegfilgrastim, pegylated granulocyte stimulating factor, granulocyte stimulating factor, or other formulations expressed by E. coli.
- Patients who are pregnant or breastfeeding
- Patients who are participating in other clinical studies or the interval of the last dose of prior study drug to the mobilization chemotherapy is less than 4 weeks (or 5 half-lives of the study drug);
- Patients with other conditions unsuitable for this study according to the investigator's judgment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: lymphoma, chemotherapy plus Mecapegfilgrastim SC on day 2
|
Etoposide 1.5-1.8g/m2,
single dose
Mecapegfilgrastim 12mg SC, on day 2 after chemotherapy
|
EXPERIMENTAL: lymphoma, chemotherapy plus Mecapegfilgrastim SC on day 5
|
Etoposide 1.5-1.8g/m2,
single dose
Mecapegfilgrastim 12mg SC, on day 5 after chemotherapy
|
EXPERIMENTAL: myltiple myeloma, chemotherapy plus Mecapegfilgrastim SC on day 2
|
Mecapegfilgrastim 12mg SC, on day 2 after chemotherapy
Cyclophosphamide 50mg/kg or 2g/m2, for 2 days
|
EXPERIMENTAL: myltiple myeloma, chemotherapy plus Mecapegfilgrastim SC on day 5
|
Mecapegfilgrastim 12mg SC, on day 5 after chemotherapy
Cyclophosphamide 50mg/kg or 2g/m2, for 2 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
percentage of successful mobilization
Time Frame: up to 28 days since the last subject were given mecapegfilgrastim
|
The percentage of subjects with ≥2×106 cell/kg CD34+ cells were collected.
|
up to 28 days since the last subject were given mecapegfilgrastim
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the number of the total CD34+ cells
Time Frame: up to 28 days since the last subject were given mecapegfilgrastim
|
the number of the total CD34+ cells which were collected from each subject
|
up to 28 days since the last subject were given mecapegfilgrastim
|
the number of leukaphereses
Time Frame: up to 28 days since the last subject were given mecapegfilgrastim
|
the number of leukaphereses needed to collect ≥2×10^6/kg CD34+ cells
|
up to 28 days since the last subject were given mecapegfilgrastim
|
Incidence of febrile neutropenia (FN)
Time Frame: up to 28 days since the last subject were given mecapegfilgrastim
|
incidence of FN during chemotherapy plus mecapegfilgrastim mobilization
|
up to 28 days since the last subject were given mecapegfilgrastim
|
times to neutrophil and platelet engraftment
Time Frame: up to 1 year post-transplantation
|
times to neutrophil and platelet engraftment after autologous stem cell transplantation
|
up to 1 year post-transplantation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
April 26, 2022
Primary Completion (ANTICIPATED)
March 31, 2024
Study Completion (ANTICIPATED)
September 30, 2024
Study Registration Dates
First Submitted
March 15, 2022
First Submitted That Met QC Criteria
March 15, 2022
First Posted (ACTUAL)
March 24, 2022
Study Record Updates
Last Update Posted (ACTUAL)
December 2, 2022
Last Update Submitted That Met QC Criteria
December 1, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Lymphoma
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Cyclophosphamide
- Etoposide
Other Study ID Numbers
- MA-ASCT-II-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Zhejiang UniversityShanghai First Song Therapeutics Co., LtdNot yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell LymphomaChina
-
Massachusetts General HospitalTG TherapeuticsTerminatedLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B-cell LymphomaUnited States
-
Novartis PharmaceuticalsCompletedDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaUnited States, Belgium, Germany, France, Italy, Korea, Republic of, Spain, Turkey
Clinical Trials on Etoposide
-
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...UnitedHealthcareActive, not recruitingSmall Cell Lung CancerUnited States
-
University Hospital, BonnCompletedEpendymomas | Recurrent Brain Tumors | Supratentorial PNETs | MedulloblastomasGermany
-
Sun Yat-sen UniversityRecruitingSmall Cell Lung CarcinomaChina
-
Guizhou Medical UniversityUnknownSmall-cell Lung CancerChina
-
Third Military Medical UniversityUnknownExtensive-stage Small Cell Lung Cancer
-
Jiangsu HengRui Medicine Co., Ltd.Enrolling by invitation
-
CephalonWithdrawn
-
Qingdao UniversityUnknownProgression Free SurvivalChina
-
Annick DesjardinsAstraZenecaCompletedGlioblastoma | GliosarcomaUnited States
-
BeiGeneActive, not recruiting